Gene Therapy Resource
The most appropriate animal model for adenoviral vector construction is the one that best matches the therapeutic hypothesis, target disease, delivery route, immune status, and required safety or efficacy readouts. Rodent models are suitable for many early studies and disease-specific evaluations, immunocompetent models are essential for assessing adenoviral immunogenicity and immune-mediated toxicity, and immunodeficient models can support vector persistence and tumor-growth studies but may underestimate immune-related risks. Non-human primates are valuable when human-like biodistribution, receptor usage, or immune responses must be clarified, but they are not required for every program.
Foundational Considerations
Selecting an animal model for adenoviral vector studies requires a balanced assessment of biological relevance, technical feasibility, and regulatory expectations. No single model fits all programs; the choice must align with the specific vector design, target disease, and intended clinical application.
The animal model should phenocopy the human disease at the molecular, cellular, and tissue levels. For example, models for liver-directed diseases require hepatic pathology that mirrors human conditions, while ocular disease models must replicate retinal or corneal degeneration patterns. The closer the model mimics human disease progression, the more predictive the efficacy and safety data will be.
Adenoviral vectors elicit both innate and adaptive immune responses. Immunocompetent models are essential for studying vector immunogenicity, but they may also clear the vector before therapeutic effect is achieved. Immunodeficient models (e.g., nude or SCID mice) allow longer vector persistence but may not predict immune-related toxicities. The choice depends on whether the goal is to study immune evasion strategies or to evaluate therapeutic efficacy in an immune-competent setting.
Species differences in receptor usage, co-stimulatory pathways, and tissue tropism can affect how well an animal model predicts human outcomes. Non-human primates (NHPs) are often considered the gold standard for adenoviral vector studies due to their closer physiological and immunological resemblance to humans. However, cost and ethical considerations frequently limit NHP use to late-stage preclinical programs. For many applications, rodents remain the primary model, especially when complemented with humanized or transgenic systems.
Model Selection by Indication
Different therapeutic areas impose distinct requirements on animal models. The following overview highlights model considerations for major disease categories targeted by adenoviral vectors.
Adenoviral vectors for CNS applications must cross the blood-brain barrier or be delivered via direct injection. Common models include transgenic mice for Alzheimer's disease, Parkinson's disease, and Huntington's disease. Models should exhibit progressive neurodegeneration and allow behavioral and biochemical readouts.
The eye is an immune-privileged site, making it attractive for adenoviral gene delivery. Models for age-related macular degeneration, retinitis pigmentosa, and Leber congenital amaurosis often involve subretinal or intravitreal vector administration, with efficacy measured by electroretinography and histology.
Adenoviral vectors have been explored for cardiovascular disorders including heart failure and coronary artery disease. Models include ischemia-reperfusion injury in rodents, myocardial infarction models, and large animal models (e.g., pigs) for translational studies. Readouts often include echocardiography, histopathology, and biomarker analysis.
For inherited disorders, models with defined genetic mutations are essential. Examples include hemophilia A/B models, Pompe disease models, and alpha-1 antitrypsin deficiency models. These models allow direct assessment of gene correction or replacement strategies.
Adenoviral vectors are widely used in cancer gene therapy, including oncolytic adenoviruses and vectors delivering therapeutic genes. Cancer models range from subcutaneous xenografts to orthotopic and genetically engineered mouse models (GEMMs). Immunocompetent models are particularly important for evaluating immune-stimulatory effects and suicide gene therapy approaches.
Practical Guidance
Beyond disease relevance, several practical factors influence model choice. These include availability of reagents, ethical considerations, cost, and the ability to perform longitudinal studies.
The model must support the intended delivery route—whether intravenous, intra-arterial, intratumoral, or direct injection into target tissues. For liver-targeting or muscle-targeting vectors, the model should allow reliable vector delivery to the target organ.
The model should enable measurement of relevant endpoints, such as vector genome copy number, transgene expression, histopathological changes, and functional outcomes. Viral vector analysis tools must be compatible with the chosen model.
Regulatory agencies often have expectations regarding animal model selection for IND-enabling studies. Models should be well-characterized and have a track record of use in gene therapy programs. Refer to FDA guidance for CMC and preclinical considerations.
The model should yield reproducible results across laboratories and studies. Standardized protocols for vector administration, sample collection, and analysis are critical. Custom adenoviral vector production services can help ensure consistent vector quality for animal studies.
Translational Roadmap
Connect model selection, experimental execution, data interpretation, and go/no-go decision-making into a single coordinated plan built around the question your gene therapy program needs to answer.
Select the animal model that best recapitulates the human disease pathology, vector tropism, and immune context. Document the rationale linking model attributes to the clinical indication and regulatory precedent.
Execute the study with defined endpoints: vector biodistribution, transgene expression, immunogenicity, histopathology, and functional outcomes. Ensure all assays are validated and sample collection follows a pre-specified plan.
Integrate efficacy, safety, and mechanistic readouts to assess the therapeutic window. Compare results across models and against historical benchmarks to contextualize findings and identify sources of variability.
Translate preclinical evidence into a clear go/no-go recommendation. Define follow-up studies—dose-ranging, combination therapies, or progression to large-animal models—that address remaining uncertainties before clinical entry.
Decision-Ready Deliverables
Every project delivers a package aligned with the approved scope—from model characterization reports to integrated summaries that support regulatory discussions.
Phenotypic, genetic, and functional validation data.
Efficacy, biodistribution, and immunogenicity tables and figures.
Study reports aligned with IND-enabling data expectations.
Interpretive review and follow-up recommendations.
Project Support
Creative Biolabs offers comprehensive services to support adenoviral vector development, from design and construction to production and characterization. Our capabilities span the entire pipeline, enabling seamless transition from bench to bedside.
From recombinant adenovirus construction to capsid-modified vectors, we provide tailored solutions for your specific program needs.
High-quality custom adenoviral vector production services ensure sufficient material for preclinical studies, with rigorous quality control and documentation.
Support for safety and toxicology studies, including biodistribution, shedding, and immunogenicity assessments required for regulatory submissions.
Selected Literature
FDA guidance describing expectations for preclinical studies, including animal model selection and characterization.
A comprehensive review of adenoviral vector biology, immunogenicity, and preclinical model considerations.
Review of commonly used animal models, their advantages, and limitations for adenoviral vector studies.
FAQ
The answers below describe model selection at a general level. The final model choice is defined for each project.
Our team of experts can help you navigate the complexities of animal model selection for your adenoviral vector program. Contact us to discuss your project requirements.
Tell us about your adenoviral vector program and the disease indication you are targeting. Our scientific team will follow up with a project-specific model selection approach.
Contact Creative BiolabsTell us about your project, and our experts will get back to you with a customized quote and proposal.
